NCT03631550 - The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

August 4, 2020

Study Completion Date

August 4, 2020

Conditions

Acute Migraine

Interventions

DEVICE

Relivion active

1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation

DEVICE

Relivion Sham

1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation

Trial Locations (12)

Clinical Research Consortium, an AMR company, Tempe

Clinical Research Consortium, an AMR company, Las Vegas

Hartford HealthCare Headache Center, Hartford

Yale School of Medicine, New Haven

Regeneris Medical, North Attleboro

Dartmouth-Hitchcock Medical Center, Lebanon

Barzilai MC, Ashkelon

Hillel Yaffe Medical Center, Hadera

Sharei Zedek MC, Jerusalem

Macabi healtcenter services, Kfar Saba

Laniado MC, Netanya

Macabi healtcenter services, Raanana